Dapagliflozin treatment in IgA nephropathy patients

JRCT ID: jRCT1031220369

Registered date:07/10/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: IgA nephropathy
• Date of first enrollment: 26/11/2021
• Target sample size: 150
• Study type: Observational

Outcome(s)

• Primary Outcome: Change in proteinuria and eGFR from baseline

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

(1) Diagnosis of IgA nephropathy by renal biopsy
(2) IgA nephropathy patients treated with dapagliflozin
(3) 20 years of age and older at the time of consent acquisition
(4) Receiving maximum tolerated dose of RAS inhibitors (excluding not tolerable case due to AE)
(5) After completion of predonine treatment
(6) eGFR more than 25 mL/min/1.73 m2
(7) Postive proteinuria
(8) Patients who have been fully informed about their participation in this study, and who have given their free and voluntary written consent based on a thorough understanding of the subject's own

Exclude criteria

(1) Patients who are taking or may start steroids or other immunosuppressive drugs during the study period
(2) Patients who cannot walk on their own and need assistance or a wheelchair to get to the hospital
(3) Patients under treatment for malignant tumors
(4) BMI less than 18
(5) Other exclusion criteria include patients deemed inappropriate as research subjects by the principal investigator

A research subject is eligible if he/she meets all of the selection criteria and none of the exclusion criteria listed above

Related Information

• Primary Sponsor: Tomohito Gohda